Results 171 to 180 of about 5,953 (226)

Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C

open access: bronze, 2020
Steven L. Flamm   +7 more
openalex   +1 more source

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

open access: yesCost Eff Resour Alloc
Jafari M   +7 more
europepmc   +1 more source

Steatotic liver disease in patients with chronic hepatitis C. [PDF]

open access: yesWorld J Hepatol
Janczura J   +6 more
europepmc   +1 more source

To treat or not to treat young children with hepatitis C?--real-life experience. [PDF]

open access: yesEur J Pediatr
Pokorska-Śpiewak M   +4 more
europepmc   +1 more source

Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study. [PDF]

open access: yesBMJ Open
Jafari M   +5 more
europepmc   +1 more source

Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up. [PDF]

open access: yesJ Clin Med
Benjaram S   +7 more
europepmc   +1 more source

UPLC Method Development and Validation for Sofosbuvir, Velpatasvir, and Voxilaprevir Determination

open access: diamond
Samson Israel. D   +4 more
openalex   +2 more sources

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

open access: gold, 2019
Alessandra Mangia   +23 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy